Pfizer Announces Positive Preliminary Results From a Proof-of-Concept Phase 2 Study of Its 20-Valent Pneumococcal Conjugate Vaccine Candidate
September 09, 2019
September 09, 2019
NEW YORK, Sept. 9 -- Pfizer, a pharmaceutical company, issued the following news release:
Pfizer Inc. (NYSE: PFE) announced today positive preliminary results following administration of three doses in a four-dose series for a Proof-of-Concept Phase 2 study (B7471003) to assess safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, being investigated for the prevention of invasive disease and otitis media caused by Streptococcus pn . . .
Pfizer Inc. (NYSE: PFE) announced today positive preliminary results following administration of three doses in a four-dose series for a Proof-of-Concept Phase 2 study (B7471003) to assess safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, being investigated for the prevention of invasive disease and otitis media caused by Streptococcus pn . . .